Anemia Clinical Trial
Official title:
Utilization of Linear Programming Approach to Develop Local Specific Food-based Complementary Feeding Recommendation for Stunting and Anemia Prevention Among Under-two Children
Verified date | March 2019 |
Source | SEAMEO Regional Centre for Food and Nutrition |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Stunting and anemia amongst under-two children are attributable to poor nutrient intakes. The study evaluates the effectiveness of nutrition education on local specific food-based complementary feeding recommendation (CFR) to improve dietary patterns and nutritional intakes, as well as reduce stunting and anemia among under-two children.
Status | Enrolling by invitation |
Enrollment | 926 |
Est. completion date | December 31, 2019 |
Est. primary completion date | October 31, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 11 Months |
Eligibility |
Inclusion Criteria: - 6-11 months old at baseline - living in selected area during the study - apparently healthy - willing to take part in the study and taken venous blood sample by getting signed consent from parents Exclusion Criteria: - the child does not present during venous blood sample collection |
Country | Name | City | State |
---|---|---|---|
Indonesia | Malang District Health Office | Malang | West Java |
Indonesia | Sambas District Health Office | Sambas | West Borneo |
Lead Sponsor | Collaborator |
---|---|
SEAMEO Regional Centre for Food and Nutrition | Health Polytechnic of Malang, Health Polytechnic of Pontianak, Indonesia University, Malang District Health Office, Ministry of Health Republic of Indonesia, Sambas District Health Office |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in anthropometric measurements | to measure the change in length measured by using WHO growth standard length-for-Age (Z-Score) before and after intervention period. | At baseline before intervention (week 0), at midpoint of intervention (week 12), at endpoint after intervention (week 24) | |
Primary | Change in hemoglobin status | to measure the change in hemoglobin (g/L) before and after intervention | At baseline before intervention (week 0), at endpoint after intervention (week 24) | |
Primary | Change in iron status | to measure the change in serum ferritin (microgram/L) before and after intervention | At baseline before intervention (week 0), at endpoint after intervention (week 24) | |
Primary | Change in zinc status | to measure the change in serum zinc (mg/L) before and after intervention | At baseline before intervention (week 0), at endpoint after intervention (week 24) | |
Secondary | Change in dietary patterns | Dietary patterns will be measured by using Dietary Diversity Score | At baseline before intervention (week 0), at midpoint of intervention (week 12), at endpoint after intervention (week 24) | |
Secondary | Change in iron intake | iron intake (mg/day) | At baseline before intervention (week 0), at midpoint of intervention (week 12), at endpoint after intervention (week 24) | |
Secondary | Change in zinc intake | zinc intake (mg/day) | At baseline before intervention (week 0), at midpoint of intervention (week 12), at endpoint after intervention (week 24) | |
Secondary | Change in calcium intake | calcium intake (mg/day) | At baseline before intervention (week 0), at midpoint of intervention (week 12), at endpoint after intervention (week 24) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |